Karolinska Development AB (STU:2I9) ROCE % : -2.65% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Karolinska Development AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Karolinska Development AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -2.65%.

Karolinska Development AB ROCE % Historical Data

The historical data trend for Karolinska Development AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB ROCE % Chart

Karolinska Development AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

50.76

-22.69

19.91

-7.65

0.43

Karolinska Development AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-2.37	-2.66	-1.39	8.37	-2.65

Karolinska Development AB ROCE % Calculation

Karolinska Development AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	0.481	/	( ( (113.852 - 0.929)	+	(112.497 - 1.034) )	/ 2 )
	=	0.481	/	( (112.923	+	111.463)	/ 2 )
	=	0.481	/	112.193
	=	0.43 %

Karolinska Development AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-2.94	/	( ( (112.497 - 1.034)	+	(111.355 - 1.161) )	/ 2 )
	=	-2.94	/	( ( 111.463	+	110.194 )	/ 2 )
	=	-2.94	/	110.8285
	=	-2.65 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Karolinska Development AB (STU:2I9) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Karolinska Development AB ROCE % Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Karolinska Development AB (STU:2I9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (STU:2I9) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

KDEV:Sweden 2I9:Germany

Address

TomtebodavAgen 23 A, Solna, SWE, SE-171 65

Website

https://www.karolinskadevelopment.com

Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.

Karolinska Development AB (STU:2I9) Headlines

No Headlines